Brought to you by 
Bavarian Nordic and PowderJect in vaccine delivery alliance
22 Jul 2002
Executive Summary
PowderJect Technologies Ltd. (needle-free injection systems) has invested $2.23mm (DKR18mm) for a 5.6% stake in Danish gene/cell therapy company Bavarian Nordic AS through the purchase of 200k common shares at $10.64 each, a 17% premium over closing price on the day the deal was announced.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- Manufacturing or Supply
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bavarian Nordic and PowderJect in vaccine delivery alliance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice